Abstract
Smad ubiquitylation regulatory factor-1 (Smurf1) is a HECT-type ubiquitin ligase. The role of Smurf1 in cell development and migration, viral autophagy and immune responses has been the subject of intensive study in recent years. Smurf1 regulates multiple biological networks, including TGF-β and BMP signaling pathways, the non-canonical pathway and the Toll-like receptor pathway, and is linked to certain diseases and disorders, such as bone formation and embryonic development disorders. Increasing evidence suggests that Smurf1 could be a good candidate for further translational studies and a potential target for novel drug design. In this review, we summarize the physiological functions of Smurf1 and its associated disorders; and discuss the current state of drug discovery in the context of the ubiquitin-proteasomal system, and feasible pharmaceutical strategies toward Smurf1 and its regulators, as well as RNA interference and structure-based chemical drug selection.
Keywords: Ubiquitylation, Ubiquitin ligase, HECT domain, Nedd4 family, Smurf1.
Current Pharmaceutical Design
Title:Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1
Volume: 19 Issue: 18
Author(s): Yu Cao and Lingqiang Zhang
Affiliation:
Keywords: Ubiquitylation, Ubiquitin ligase, HECT domain, Nedd4 family, Smurf1.
Abstract: Smad ubiquitylation regulatory factor-1 (Smurf1) is a HECT-type ubiquitin ligase. The role of Smurf1 in cell development and migration, viral autophagy and immune responses has been the subject of intensive study in recent years. Smurf1 regulates multiple biological networks, including TGF-β and BMP signaling pathways, the non-canonical pathway and the Toll-like receptor pathway, and is linked to certain diseases and disorders, such as bone formation and embryonic development disorders. Increasing evidence suggests that Smurf1 could be a good candidate for further translational studies and a potential target for novel drug design. In this review, we summarize the physiological functions of Smurf1 and its associated disorders; and discuss the current state of drug discovery in the context of the ubiquitin-proteasomal system, and feasible pharmaceutical strategies toward Smurf1 and its regulators, as well as RNA interference and structure-based chemical drug selection.
Export Options
About this article
Cite this article as:
Cao Yu and Zhang Lingqiang, Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1, Current Pharmaceutical Design 2013; 19 (18) . https://dx.doi.org/10.2174/1381612811319180007
DOI https://dx.doi.org/10.2174/1381612811319180007 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer?s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Papillary Thyroid Carcinoma in Pediatric Age: An Example of a Rare Tumour Managed Within a Cooperative Comprehensive Project
Current Pediatric Reviews Identification of a RhoA- and SRF-Dependent Mechanism of Androgen Action that is Associated with Prostate Cancer Progression
Current Drug Targets Carbon Nanofiber Reinforced Polycaprolactone Fibrous Meshes by Electrostatic Co-spinning
Current Nanoscience Quantitative Structure-Wavelength Relationship Modeling of Porphin -Derivative Photosensitizers
Combinatorial Chemistry & High Throughput Screening Platelet-Rich and Platelet-Poor Plasma Might Play Supportive Roles in Cancer Cell Culture: A Replacement for Fetal Bovine Serum?
Anti-Cancer Agents in Medicinal Chemistry Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Cerebral Angiogenesis and Expression of Angiogenic Factors in Aging Rats after Exercise
Current Neurovascular Research The Use of the Bone Seeking Radiopharmaceutical 153-Samarium-EDTMP as an Adjuvant Treatment for Osteosarcoma: A Review
Current Medical Imaging Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents ES-MDA: Enhanced Similarity-based MiRNA-Disease Association
Current Protein & Peptide Science Editorial (Thematic Issue: Endocrine Related Cancer: From Stem Cells to New Drug Targets)
Current Medicinal Chemistry Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Current Pharmaceutical Design Recent Patents Review in Three Dimensional Ultrasound Imaging
Recent Patents on Biomedical Engineering (Discontinued) HUHS1015 Induces Necroptosis and Caspase-Independent Apoptosis of MKN28 Human Gastric Cancer Cells in Association with AMID Accumulation in the Nucleus
Anti-Cancer Agents in Medicinal Chemistry WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of β-Catenin during Oxidant Stress with Limited Effects upon Neuronal Autophagy
Current Neurovascular Research Role of Hexokinase and VDAC in Neurological Disorders
Current Molecular Pharmacology The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Targeting SKCa Channels in Cancer: Potential New Therapeutic Approaches
Current Medicinal Chemistry